News & Updates

Oral ENT-01 safely and significantly improves constipation in patients with Parkinson’s disease (PD), results of a phase IIb study have shown.

In a broad range of patients with HFrEF* and iron deficiency, the administration of IV ferric derisomaltose (FDI) was associated with a lower risk of recurrent hospitalization for heart failure (HHF) and cardiovascular (CV) death compared with standard of care (SoC), findings from the IRONMAN** trial have shown.

Treatment with rivaroxaban for 3 months leads to a safe and successful reduction of recurrent venous thromboembolism (VTE) risk compared to treatment for 6 weeks in patients with isolated distal deep vein thrombosis (DVT), a study has shown.

Close blood pressure (BP) monitoring and more intensive and combined antihypertensive therapy are needed when there is a high prevalence of uncontrolled arterial hypertension (AH) despite the successful coarctation of the aorta (CoA) correction and use of relatively low doses of antihypertensive drugs, suggests a recent study.

In the phase III part of the PANAMO trial, the anti-C5a monoclonal antibody vilobelimab, when added to standard of care (SoC), improved survival in COVID-19 patients who required invasive mechanical ventilation (IMV).

A recent study has demonstrated the safety and efficacy of bulevirtide (BLV) monotherapy for 48 weeks in difficult-to-treat patients with hepatitis delta virus (HDV)-related compensated cirrhosis and clinically significant portal hypertension (CSPH).